MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma (pages 252–266)F. Burel-Vandenbos, M. Ngo-Mai, B. Dadone, I. Di Mauro, S. Gimet, E. Saada-Bouzid, V. Bourg, F. Almairac, D. Fontaine, T. Virolle and F. Pedeutour
Version of Record online: 4 APR 2016 | DOI: 10.1111/nan.12320
The rare occurrence of MET amplification in glioblastomas represents a therapeutic target. In this study strong immunohistochemical labelling of MET was found to be associated with gene amplification and is, therefore, proposed as a screening tool to direct molecular investigation of glioblastomas.